Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.

Authors :: El Ahmar, Nourhan
Matar, Sayed
Jegede, Opeyemi
Nabil Laimon, Yasmin
Savla, Varunika
Bagheri Sheshdeh, Aseman
Denize, Thomas
Mohanna, Razan Assaad
Choueiri, Toni K.
Catalano, Paul J.
Braun, David A.
Haas, Naomi B.
Hammers, Hans J.
Bilen, Mehmet Asim
Stein, Mark N.
Sosman, Jeffrey A.
Wu, Catherine J.
McDermott, David F.
Atkins, Michael B.
Signoretti, Sabina
Source :: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p448-448, 140p
Publication Year :: 2024

Full Text Access

Tools